In addition to reducing the requirement for insulin and a liver fat biomarker, EndoBarrier treatment reduced 10-year CVD risk by clinically useful amounts in patients with poorly controlled diabetes and obesity. These data suggest that EndoBarrier treatment in 100 patients could prevent between 8 and 9 events of CHD or stroke and save between 6 and 7 lives over the next 10 years, if effects were maintained.